Dr Reddy’s launches generic hemophilia inj.
Dr Reddy’s Laboratories has said it has launched generic desmopressin acetate injection indicated for treatment of hemophilia, in the US. The company has launched desmopressin acetate injection USP, 4 mcg/mL single-dose ampules in the US market, Dr Reddy’s Laboratories said in a filing to the BSE.
According to IQVIA health data, the desmopressin acetate injection USP brand and generic market had US sales of approximately $20.9 million MAT for the 12 months ended March 2020, it added.
“The launch of desmopressin injection demonstrates a strong, growing collaboration with SunGen Pharma. We look forward to future opportunities with this company,” Marc Kikuchi, CEO – North America Generics, Dr Reddy’s Laboratories, said. The product is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than five per cent.
“We are pleased to be working with Dr Reddy’s for this launch. The launch of desmopressin demonstrates our strong development capabilities. We look forward to collaborating further to bring specialty pharmaceutical drugs to the markets around the world,” Isaac Liu, Co-CEO, SunGen, said.